Sugi Predict

Sugi Predict / Compounds / SCHEMBL521435

SCHEMBL521435

SCHEMBL521435

CC(C)(C)OC(=O)N1C2CCC1C(=O)C2

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.54
▸ CHRM1 P11229 1/20 0.54
▸ CHRM3 P20309 1/20 0.54
▸ PREP P48147 4/20 0.44
▸ HSD11B1 P28845 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ GPR119 Q8TDV5 1/20 0.35
▸ ELANE P08246 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL521781 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL1445058 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL521276 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL30000644 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL24616534 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL24616413 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL30278375 0.87 CHRM2 (0.51) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL21588272 0.87 CHRM2 (0.51) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL31045746 0.86 CHRM2 (0.55) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL21308104 0.86 CHRM2 (0.50) CHRM2CHRM1CHRM3PREPHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4087583-B1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-04-22 — — EP disclosed
EP-3810615-B1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-01-28 — — EP disclosed
US-12319698-B2 Proteasome activity enhancing compounds Kineta, Inc. (US) 2025-06-03 — — US disclosed
CN-119698412-A 5-HT2A receptor agonist, and preparation method and application thereof 上海翊石医药科技有限公司 2025-03-25 — — CN disclosed
CN-112585132-B Proteasome activity enhancing compounds 优曼尼蒂公司 2025-02-28 — — CN disclosed
WO-2025021120-A1 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2025-01-30 — — WO disclosed
WO-2024220747-A2 FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF Lysoway Therapeutics, Inc. (US) 2024-10-24 — — WO disclosed
US-20230183256-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS YUMANITY THERAPEUTICS, INC. 2023-06-15 — — US disclosed
US-20230140132-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2023-05-04 — — US disclosed
US-20230140132-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2023-05-04 — — US disclosed
US-20080132486-A1 Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them GEORGETOWN UNIVERSITY (US) 2008-06-05 — — US disclosed
US-20080132486-A1 Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them GEORGETOWN UNIVERSITY (US) 2008-06-05 — — US disclosed
WO-2005000806-A2 LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM GEORGETOWN UNIVERSITY (US) 2005-01-06 — — WO disclosed
WO-2005000806-A2 LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM GEORGETOWN UNIVERSITY (US) 2005-01-06 — — WO disclosed
US-6579878-B1 2-((3-pyridyl)methyl)-7-azabicyclo(2.2.1)heptane; agonists of nicotinic cholinergic receptors; dysfunction of the central and autonomic nervous systems TARGACEPT, INC. 2003-06-17 — — US disclosed
WO-2002004442-A9 AZABICYCLIC COMPOUNDS AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS TARGACEPT INC (US) 2002-06-13 — — WO disclosed
US-6384228-B2 EPIBATIDINE; ANALGESICS; ANIMAL EXTRACTS NIHON MEDI-PHYSICS CO., LTD. (JP) 2002-05-07 — — US disclosed
US-20020010339-A1 METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF NIHON MEDI-PHYSICS CO., LTD. (JP) 2002-01-24 — — US disclosed
WO-2002004442-A2 AZABICYCLIC COMPOUNDS AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS TARGACEPT, INC. (US) 2002-01-17 — — WO disclosed
US-6060473-A 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands UCB S.A. - DTB (BE) 2000-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132486-A1 Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them CHRNA5, OPRL1, TAAR5 CHRM2 47/4885CHRM1 25/4885CHRM3 41/4885
US-20020010339-A1 METHOD FOR SYNTHESIS OF HALOPYRIDYL-ACYCLOPENTANE DERIVATIVE AND INTERMEDIATE THEREOF DHPS, ALAD, HAAO CHRM2 4586/4885CHRM1 4158/4885CHRM3 4670/4885
US-12319698-B2 Proteasome activity enhancing compounds PSMG3, PSME3, PSMC4 CHRM2 4601/4885CHRM1 4623/4885CHRM3 4485/4885
US-20230140132-A1 ARGINASE INHIBITORS AND METHODS OF USE ARG1, ARG2, PRMT1 CHRM2 726/4885CHRM1 738/4885CHRM3 1948/4885
US-20230183256-A1 PROTEASOME ACTIVITY ENHANCING COMPOUNDS PSMG3, PSME3, PSMC4 CHRM2 4601/4885CHRM1 4623/4885CHRM3 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.